Schröder S, Komminoth P, Padberg B, Heitz P U
Department Pathologie, Universität, Zürich.
Pathologe. 1995 Sep;16(5):307-14. doi: 10.1007/s002920050107.
The aim of morphological tumour diagnosis is to answer clinical questions on type, biological potential, prognosis and aetiology of individual neoplasms. The limitations and perspectives of different methods used in the diagnosis of adrenal tumours, ranging from histology to molecular genetic DNA analyses, are described. When surgical specimens from adrenal neoplasms cannot be typed on the basis of histology and/or with clinica data (e.g., endocrine symptoms and history) as adrenocortical tumours, phaeochromocytomas or metastases to the adrenal, immunohistological investigations with a panel of different antibodies are necessary. After identification of the tissue derivation of an individual adrenal tumour, its biological potential must be assessed. Among adrenocortical neoplasms, adenomas and carcinomas can be distinguished by evaluation of various histological parameters (including structural features and signs of invasion) according to defined algorithms. In addition, conventional histology (by estimation of mitotic activity) allows the discrimination of tumours with especially high malignant potential from other adrenocortical carcinomas. In contrast, among adrenomedullary tumours even the combined use of histological, immunohistological and DNA cytophotometric techniques only allows the definition of risk groups (benign versus suggestive of malignancy), while reliable recognition of an individual malignant phaeochromocytoma is so far impossible. The question as to whether a particular phaeochromocytoma represents a sporadic tumour or a neoplasm inherited as one feature of a defined syndrome cannot be answered with the above methods, but only by the application of molecular genetic techniques.
形态学肿瘤诊断的目的是回答关于个体肿瘤的类型、生物学潜能、预后及病因的临床问题。本文描述了从组织学到分子遗传DNA分析等用于肾上腺肿瘤诊断的不同方法的局限性及前景。当肾上腺肿瘤的手术标本无法基于组织学和/或临床数据(如内分泌症状和病史)归类为肾上腺皮质肿瘤、嗜铬细胞瘤或肾上腺转移瘤时,就需要使用一组不同抗体进行免疫组织学研究。在确定个体肾上腺肿瘤的组织来源后,必须评估其生物学潜能。在肾上腺皮质肿瘤中,腺瘤和癌可根据既定算法通过评估各种组织学参数(包括结构特征和浸润迹象)来区分。此外,传统组织学(通过估计有丝分裂活性)能够将具有特别高恶性潜能的肿瘤与其他肾上腺皮质癌区分开来。相比之下,在肾上腺髓质肿瘤中,即使联合使用组织学、免疫组织学和DNA细胞光度测定技术,也只能定义风险组(良性与疑似恶性),而目前还无法可靠识别单个恶性嗜铬细胞瘤。上述方法无法回答特定嗜铬细胞瘤是散发性肿瘤还是作为特定综合征的一个特征遗传而来的肿瘤这一问题,只有应用分子遗传学技术才能回答。